Edgewise Therapeutics
Jessica Tolley has a diverse work experience in the field of research and scientific analysis. Jessica started their career as a Research Intern at Sanford-Burnham Medical Research Institute in 2006, where they focused on genetics research and performed metabolic assays. Jessica continued their work at the institute as a Laboratory Assistant, responsible for media preparation and training students and technicians.
In 2011, Jessica transitioned to the role of Research Technician at Sanford-Burnham Medical Research Institute, where they further contributed to genetics research, particularly in the area of Drosophila Melanogaster. Jessica performed various metabolic assays and played a key role in the publication of scientific findings in Cell Metabolism.
In 2012, Jessica joined BASF as a QC Associate Scientist, conducting quality control analysis of raw materials and finished enzyme products. Jessica was involved in method development and validation for enzyme activity determination.
From 2018 to 2021, Jessica worked as a Research Associate at Oregon Health & Science University. Jessica'swork focused on the evaluation and discovery of potential diagnostic reagents for pancreatic cancer. Jessica utilized in vitro screens and expression techniques to identify and optimize VHH binders.
Currently, Jessica is employed at Edgewise Therapeutics, starting as a Senior Research Associate in 2021 and then transitioning to the role of Associate Scientist in 2022. Unfortunately, the end dates for their roles at Edgewise Therapeutics are not provided.
Jessica Tolley pursued their Bachelor of Arts degree in Psychology at UC San Diego from 2004 to 2008.
This person is not in any offices
Edgewise Therapeutics
1 followers
Edgewise Therapeutics is a biotechnology company harnessing proven expertise and understanding of skeletal muscle physiology to develop novel, transformative therapies for serious muscle diseases. Based in Boulder, Colorado, we have built a state-of-the-art muscle research facility to capitalize on new insights into the nature and consequences of muscle adaptation and injury with disease. Edgewise recently closed it’s Series B financing round which will support the advancement of Edgewise Therapeutic’s lead product candidate into clinical development for Duchenne and Becker Muscular Dystrophy (DMD and BMD) as well as expansion of the company’s pipeline. The company’s leadership team has founded multiple biotechnology startups, several of which have gone on to become publicly-traded companies and brings to bear a depth of experience in drug discovery, development and commercialization.